Plus Therapeutics (PSTV) Return on Capital Employed (2011 - 2026)
Plus Therapeutics (PSTV) reported Return on Capital Employed of 185.74% for Q1 2026, down 141521.0% year-over-year from N/an in Q1 2025, and up 37.07% quarter-over-quarter from 295.13% in Q4 2025.
Plus Therapeutics (PSTV) Return on Capital Employed (2011 - 2026) Analysis & Trends
Plus Therapeutics (PSTV) has 16 years of Return on Capital Employed data on file, last reported at 185.74% in Q1 2026.
- Return on Capital Employed for Q1 2026 came in at 185.74%, down 141521.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 185.74% (down 141521.0% YoY), and the FY2025 annual result was 1832.1%, up 160742.0% from the prior year.
- Return on Capital Employed advanced to 185.74% in Q1 2026 per PSTV's latest filing, from 295.13% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 1229.48% in Q1 2025 and troughed at 1505.15% in Q3 2025.
- A 5-year average of 130.16% and a median of 169.44% in 2022 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2024 and 2025: Return on Capital Employed soared 99748 bps in 2024, then tumbled 199083 bps in 2025.
- A 5-year view of Return on Capital Employed shows it stood at 169.44% in 2022, then slumped by 390 bps to 829.45% in 2023, then soared by 120 bps to 168.03% in 2024, then slumped by 276 bps to 295.13% in 2025, then soared by 37 bps to 185.74% in 2026.
- Business Quant data shows PSTV's Return on Capital Employed at 185.74% in Q1 2026, 295.13% in Q4 2025, and 1505.15% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | 450.31% |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 51.73% |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | -107.40% |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | -50.43% |
| 10 | Plus Therapeutics | 37.48 Mn | 22.37 Mn | - | -185.74% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -185.74% |
| Dec 31, 2025 | -295.13% |
| Sep 30, 2025 | -1,505.15% |
| Jun 30, 2025 | -328.61% |
| Mar 31, 2025 | 1,229.48% |
| Dec 31, 2024 | 168.03% |
| Sep 30, 2024 | 485.68% |
| Jun 30, 2024 | 136.01% |
| Mar 31, 2024 | 628.03% |
| Dec 31, 2023 | -829.45% |
| Sep 30, 2023 | -469.92% |
| Jun 30, 2023 | -479.69% |
| Mar 31, 2023 | -294.80% |
| Dec 31, 2022 | -169.44% |
| Sep 30, 2022 | -122.42% |
| Jun 30, 2022 | -103.53% |
| Mar 31, 2022 | -76.06% |
| Dec 31, 2021 | -71.40% |
| Sep 30, 2021 | -89.81% |
| Jun 30, 2021 | -87.66% |